Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis.
Hepatic metastasis is a primary cause for failure of locoregional therapy in colorectal cancer. Increased expression of osteopontin (OPN), a ligand for alpha(v)beta3 integrin and CD44 receptors, is associated with metastasis in several types of cancer. However, the mechanism by which OPN mediates metastasis in colorectal cancer remains unknown. We hypothesized that OPN mediates invasion of colon cancer cells through basement membrane and migration through extracellular matrix (ECM). In this study, we used CT26 murine colon adenocarcinoma cells syngeneic to BALB/c mice to generate cell lines (pS-OPN) in which OPN expression was suppressed through small interfering RNA (siRNA) plasmids. CT26 wild-type cells (WT) and CT26 cells stably expressing murine-mismatch siRNA (pS-MM) served as controls. Western blotting quantified OPN protein levels and our most downregulated clone, pS-OPN-A4, demonstrated a mean 3.0-fold decrease in OPN protein expression versus WT. In vitro cell motility and invasiveness were decreased in pS-OPN-A4 by 3.6-fold (P = 0.004 versus WT) and 4.1-fold (P = 0.01 versus WT), but proliferation was similar amongst cell lines. We demonstrated that OPN suppression significantly correlates with MMP-2 downregulation. In vivo hepatic metastasis was assessed by quantifying liver weights and surface tumor nodules in 33 BALB/c mice (11/group) subjected to intrasplenic injection of tumor cells. pS-OPN-A4 resulted in a 50.4% decrease in mean liver weight compared with WT (3.79 +/- 1.49 g versus 1.88 +/- 1.34 g, P = 0.009). Only 18% of pS-OPN-A4 livers had >20 metastatic surface nodules compared with 89% for WT and 75% for pS-MM-V6. This study demonstrates that RNA interference stably reduces CT26 tumor expression of OPN and significantly attenuates CT26 colon cancer metastasis by diminishing tumor cell motility and invasiveness.
Wai
Philip Y
PY
MSRB, Room 437, 704 Research Drive, Duke University Medical Center, Durham, NC 27710, USA. philip.wai@duke.edu
Mi
Zhiyong
Z
Guo
Hongtao
H
Sarraf-Yazdi
Shiva
S
Gao
Chengjiang
C
Wei
Junping
J
Marroquin
Carlos E
CE
Clary
Bryan
B
Kuo
Paul C
PC
D000230:Adenocarcinoma / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D000818:Animals; D015153:Blotting, Western; D002465:Cell Movement; D003110:Colonic Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D020868:Gene Silencing / Q000187:drug effects*; D015316:Genetic Therapy; D066298:In Vitro Techniques; D008113:Liver Neoplasms / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size; D053495:Osteopontin; D034741:RNA, Small Interfering / Q000502:physiology*; D012795:Sialoglycoproteins / Q000235:genetics* / Q000378:metabolism
D034741:RNA, Small Interfering; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; D053495:Osteopontin; D020778:Matrix Metalloproteinase 2